For more than 20 years, the European information network on drugs and drug addiction (Reitox), has been the cornerstone of the European drug monitoring and reporting system, to which it contributes by collecting, analysing, interpreting and disseminating data at national level, as well as by defining the tools for monitoring. The EMCDDA 2025 strategy, endorsed in 2016, aims at contributing to a healthier and more secure Europe. In this context, Reitox is currently defining the new strategic goals for the network as a whole and how these will be operationalised and achieved.
Drugs and drug-related harms continue to challenge prison systems in Europe and interventions in this setting must be driven by evidence gathered through monitoring, data-collection and research. The remarks come in conclusions published by the World Health Organization Regional Office for Europe (WHO–Europe), in collaboration with Public Health England and the EMCDDA.
Today cannabis is sold openly in 573 ‘coffeeshops’ operating in 103 of the 380 municipalities in the Netherlands.
Facilitating evidence-based health decision-making among professionals, patients and policymakers will be just one of the issues discussed today by EMCDDA Director Alexis Goosdeel and Chief Executive Officer of the Cochrane Collaboration Mark Wilson.
A call for abstracts is now open for the 9th annual conference of the European Society for Prevention Research (EUSPR).
The Justice and Home Affairs Council has adopted today Council conclusions on alternatives to coercive sanctions for drug using offenders.
Together, we the Heads of EU agencies and Joint undertakings commit to zero tolerance towards sexual harassment and we cannot and will not accept harassment of any form in our agencies.
The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EU drugs agency (EMCDDA).
The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in around 60 European cities and towns (hereinafter referred to as ‘cities’) to explore the drug-taking habits of those who live in them. The results provide a valuable snapshot of the drug flow through the cities involved, revealing marked geographical variations*.
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 19 December 2017.
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 19 December 2017.
EMCDDA Director Alexis Goosdeel is in Switzerland today for a two-day meeting with representatives of the Federal Office of Public Health (FOPH).
The United Nations Commission on Narcotic Drugs (CND), the central UN policy-making body on drug-related matters, holds its 61st session in Vienna from 12–18 March 2018.
The Central Asian Drug Action Programme (CADAP), is currently in its sixth phase and reflects the EU’s long-term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction.
Environmental prevention policies and interventions seek to limit opportunities for unhealthy or risky behaviour or promote the availability of healthier options in order to prevent problems associated with substance use. They do so by altering the environment in ways that can unconsciously influence behaviour, thus complementing more established approaches that seek to build knowledge and skills.
In a new report published today, Environmental substance use prevention interventions in Europe, the EMCDDA offers a first operational definition of the concept and an initial overview of where and how such interventions are being used in the region.
Today, EMCDDA Director Alexis Goosdeel is in Brussels for an exchange of views with the European Parliament’s Committee for Environment, Public Health and Food Safety (ENVI).
On 22 January 2018, Vermont became the ninth US state to legalise possession of cannabis for recreational purposes, when Governor Phil Scott (Republican) signed House Bill 511 (Text of Act as passed by House and Senate). The law will take effect on 1 July 2018.
As of mid-January, more than 50 000 people had already participated in the European Web Survey on Drugs, a pilot project designed to improve understanding of patterns of drug use at European level.
This month, the EMCDDA has embarked on work under its Programming Document 2018–20, adopted by the Management Board on 14 December 2017. At its heart is the agency’s vision ‘to contribute to a healthier and more secure Europe’.
Director of the European Institute for Gender Equality (EIGE) Virginija Langbakk and EMCDDA Director Alexis Goosdeel are at the European Parliament today where they will present to the Committee on Civil Liberties, Justice and Home Affairs (LIBE).
This month, the EMCDDA has assumed the chairmanship of the EU Agencies’ Network on Scientific Advice (EU-ANSA), one of the sub-networks operating under the tutelage of the Heads of EU agencies network. Its specific purpose is to allow dialogue between senior scientific staff from agencies with a strong science component to their work and to provide scientific and technical advice to EU institutions, Member States and other relevant EU policymakers.
EMCDDA Director Alexis Goosdeel is paying an official visit to the European Centre for Disease Prevention and Control (ECDC) in Stockholm today where he will spend two days discussing opportunities for further collaboration between the two agencies with ECDC Director Andrea Ammon.
In 2013, findings of a first study on drug squads were published in the EMCDDA Paper series. A follow-up study was carried out in 2015 and resulted in the production of this paper. The focus of this limited update is monitoring and analysing changes in the number of specialised drug squads and their staffing levels between 2012 and 2015.
This poster was presented during the WHO Conference on Prison Health, 11-12 December 2017, Lisbon, Portugal. It presents current available data on prevalence of drug use and expert ratings on the availability and level of provision of selected drug interventions for drug users in prison, collected by the EMCDDA national focal points in EU Member States, Turkey and Norway, and supplemented with information from literature reviews.
The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces once again next summer to hold the seventh European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’.
This paper presents the EMCDDA’s current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction — building on the work completed in this area and expanding to reflect the academic research underpinning this work and the developments observed.
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 15 November 2017, the Council decided that furanylfentanyl should be subject to control measures across the Member States.
This publication presents the data and findings of the risk assessment on N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 25 September 2017, the Council decided that acryloylfentanyl should be subject to control measures across the Member States.